Currently, BridgeBio Pharma Inc [BBIO] is trading at $51.18, up 1.59%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BBIO shares have gain 11.38% over the last week, with a monthly amount glided 8.66%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Truist started tracking the stock with Buy rating on July 21, 2025, and set its price target to $66. On July 14, 2025, Jefferies initiated with a Buy rating and assigned a price target of $70 on the stock. Oppenheimer upgraded its rating to a Outperform but stick to its price target of $60 on July 09, 2025. Wolfe Research initiated its recommendation with a Outperform and recommended $49 as its price target on June 17, 2025. Redburn Atlantic started tracking with a Buy rating for this stock on March 31, 2025, and assigned it a price target of $50. In a note dated October 16, 2024, Scotiabank initiated an Sector Outperform rating.
This stock has fluctuated between a low of $21.72 and a high of $50.51 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $72 within the next 12 months. BridgeBio Pharma Inc [NASDAQ: BBIO] shares were valued at $51.18 at the most recent close of the market. An investor can expect a potential return of 40.68% based on the average BBIO price forecast.
Analyzing the BBIO fundamentals
Trailing Twelve Months sales for BridgeBio Pharma Inc [NASDAQ:BBIO] were 235.81M which represents 4999.86% growth. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -2.78%, Pretax Profit Margin comes in at -3.31%, and Net Profit Margin reading is -3.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.72, Equity is 0.51 and Total Capital is -0.72. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.5.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 50.00 points at the first support level, and at 48.82 for the second support level. However, for the 1st resistance point, the stock is sitting at 52.11, and for the 2nd resistance point, it is at 53.04.
Ratios To Look Out For
To put it in perspective, the Current Ratio for BridgeBio Pharma Inc [NASDAQ:BBIO] is 5.19. Further, the Quick Ratio stands at 5.08, while the Cash Ratio is 4.26. Considering the valuation of this stock, the price to sales ratio is 41.49.
Transactions by insiders
Recent insider trading involved HOMCY CHARLES J, Director, that happened on Aug 08 ’25 when 0.25 million shares were sold. Director, HOMCY CHARLES J completed a deal on Aug 11 ’25 to sell 50000.0 shares. Meanwhile, Chief Accounting Officer Apuli Maricel sold 1000.0 shares on Aug 07 ’25.
